Filter results
Type
Audience
Last updated
Topics
-
MRFF Genomics Health Futures Mission Roadmap and Implementation Plan Refresh National Consultation Report – January 2025
Resources › Publications7 March 2025 - This report summarises the consultation on the strategic documents for the Genomics Health Futures Mission between 14 October 2024 and 8 November 2024. The Genomics Health Futures Mission is a Medical Research Future Fund (MRFF) mission.
-
AHPPC statement on testing, tracing, isolating and quarantining in high levels of COVID-19 community transmission
News and media30 December 2021 - A statement from the Australian Health Protection Principal Committee (AHPPC) on test, trace, isolate and quarantine (TTIQ) in the context of high levels of COVID-19 community transmission.
-
Coronavirus (COVID-19) – Video – Professor Tom Calma AO – Keeping Medical Appointments
Resources › Videos18 May 2020 - Professor Tom Calma AO explains why it's important for Aboriginal and Torres Strait Islander people to keep up with their medical appointments during the coronavirus outbreak.
-
Medical Research Future Fund consumer webinar on the Post-Acute Sequelae of COVID-19 Research Plan (6 September 2023) – responses to questions
Resources › Publications23 April 2024 - On 6 September 2023, we co-hosted a webinar on the Post-Acute Sequelae of COVID-19 (PASC) Research Plan with the Consumers Health Forum of Australia. This document responds to questions raised by consumers during the webinar.
-
Budget 2019–20: Improving Access to Medicines – Stoma Appliance Scheme new listings
Resources › Publications20 April 2022 - This Budget fact sheet outlines how the Government will support people with stomas to manage their condition by adding two new and fully subsidised stoma care products to the Stoma Appliance Scheme.
-
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Medicines review protocol
Resources › Publications18 December 2019 - This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS I.
-
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol
Resources › Publications4 July 2019 - This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II.
-
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Medicines review protocol
Resources › Publications18 December 2019 - This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS VI.
-
Privacy notice for vaccination providers using the COVID-19 Vaccine Administrative System (CVAS)
Using our websites › Website privacy policy5 May 2025 - Find out how we manage any personal information we collect in relation to the COVID-19 Vaccine Administrative System (CVAS).
-
National Site of Recognition for Thalidomide Survivors and their Families
Our work › Australian Thalidomide Survivors Support Program5 February 2024 - The National Site of Recognition for Thalidomide Survivors and their Families was established by the Australian Government to acknowledge the thalidomide tragedy in Australia.